Last reviewed · How we verify
Infuvite Adult (DEXPANTHENOL)
At a glance
| Generic name | DEXPANTHENOL |
|---|---|
| Sponsor | Pfizer |
| Drug class | dexpanthenol |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1953 |
Approved indications
- Arthropod bite wound
- Contact dermatitis due to poison oak
- Diaper rash
- Disorder of skin
- Eczema
- Gastroparesis
- Paralytic Ileus Prevention
- Paralytic ileus
- Toxicodendron radicans
Common side effects
- Pneumonia aspiration
- Gastrooesophageal reflux disease
- Coma
- Somnolence
- Tumour pain
- Underdose
- Female genital tract fistula
- Anterior segment ischaemia
- Incorrect route of product administration
- Pulmonary vein occlusion
- Vaginal flatulence
- Febrile bone marrow aplasia
Key clinical trials
- Performance and Safety of IRIDIUM GARZE in Blepharitis or Blepharconjunctivitis Adjuvant Treatment (NA)
- Subcutaneous Dexpanthenol Administration and Wound Epithelialization (NA)
- Scalp Care Efficacy Evaluation for Premium Revitalizing Elixir (NA)
- Scalp Care Efficacy Evaluation for Premium Scalp Revitalizing Essence (NA)
- Instant Flush Redness Clinical Efficacy Study (NA)
- Using Dexpanthenol Cream to Prevent Lip Corner Cracks in Children After Tonsil/Adenoid Surgery (NA)
- Prostaglandin Analog Eyelash Serum and Ocular Surface Health: A Prospective Study (NA)
- Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Infuvite Adult CI brief — competitive landscape report
- Infuvite Adult updates RSS · CI watch RSS
- Pfizer portfolio CI